Abstract
This chapter discusses the preparation of blood–brain barrier crossing nerve growth factor stimulators for the stimulation of neural axons in nerve cells in treating Parkinson's disease. Neurological diseases are associated with the death of or injury to neuronal cells. It is found that although nerve growth factors currently exist, they do not readily cross the blood–brain barrier, they are unstable in plasma, and they have poor drug delivery properties. The preparation of 1-(4-benzyl-piperidin-1-yl)-2-bromo-ethanone is described. Bromoacetic acid (3.99 mmol) dissolved in 30 ml CH2Cl2 is treated with diisopropylcarbodiimide (6.78 mmol) and after 30 minutes, a white precipitate formed that is removed by filtration. It is found that the neurotrophic agents consisting of 1,2,3,4-tetrahydoisoquinoline, (I), and azo amino acid derivatives, (II), respectively, are prepared as well as used in the treatment of Parkinson's disorder and related neurological diseases. It is observed that bicyclic amino acid derivatives, (III), are effective as metabotropic glutamate receptor ligands and used in the treatment of neuronal cell damage associated with Parkinson's disease. It is shown that acetamidobenzamide derivatives, (V), are effective in treating dopamine-associated neurodegenerative disorders, including Parkinson's disorder.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Significant Pharmaceuticals Reported in US Patents
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
